套细胞淋巴瘤(MCL)占所有非霍奇金淋巴瘤(NHL)病例的近2-6%,在过去的几十年中,发病率稳步上升。尽管许多患者对前期治疗有足够的反应,在MCL管理过程中,短期缓解和快速复发具有挑战性.在这方面,对于复发/难治性(R/R)疾病的最佳治疗方案尚无共识,国际准则表明,建议的方法存在很大差异。在过去的十年中,在R/RMCL的治疗领域引入了新的试剂。自从引入布鲁顿酪氨酸激酶(BTK)抑制剂以来,R/RMCL患者的治疗算法和反应发生了巨大变化。然而,BTK电阻是常见的,需要进一步研究以开发具有更持久反应的新型药剂。靶向B细胞受体(BCR)信号的新型药物已显示出临床活性和可耐受的安全性。然而,由于在大多数临床试验中对这些新型药物的反应仍然适中,在临床前和早期临床环境中研究了联合用药策略,以确定新型药物的联合用药是否比单一药物表现出更好的持续应答.在这份报告中,我们提供了最新的文献综述,涵盖了有关R/RMCL治疗新疗法的安全性和有效性的最新临床数据.
Mantle cell lymphoma (MCL) accounts for nearly 2-6% of all non-Hodgkin lymphoma (NHL) cases, with a steady incidence increase over the past few decades. Although many patients achieve an adequate response to the upfront treatment, the short duration of remission with rapid relapse is challenging during MCL management. In this regard, there is no consensus on the best treatment options for relapsed/refractory (R/R) disease, and the international guidelines demonstrate wide variations in the recommended approaches. The last decade has witnessed the introduction of new agents in the treatment landscape of R/R MCL. Since the introduction of Bruton\'s tyrosine kinase (BTK) inhibitors, the treatment algorithm and response of R/R MCL patients have dramatically changed. Nevertheless, BTK resistance is common, necessitating further investigations to develop novel agents with a more durable response. Novel agents targeting the B-cell receptor (BCR) signaling have exhibited clinical activity and a well-tolerable safety profile. However, as the responses to these novel agents are still modest in most clinical trials, combination strategies were investigated in pre-clinical and early clinical settings to determine whether the combination of novel agents would exhibit a better durable response than single agents. In this report, we provide an updated literature
review that covers recent clinical data about the safety and efficacy of novel therapies for the management of R/R MCL.